Value investors often look for stocks that are not just statistically cheap, but also financially sound enough to avoid the classic value trap. A practical way to combine those goals is to run a Decent Value screen, a methodology that requires a strong valuation score while still leaving room for decent profitability, health, and growth. GLOBUS MEDICAL INC - A (NYSE:GMED) is one company that currently passes that test, with a fundamental rating of 7 out of 10 and a balanced profile across the metrics that matter most for this strategy.
A screen designed to avoid value traps
The Decent Value screen starts with valuation, but it does not stop there. A low price-to-earnings ratio can sometimes point to a business in decline, so the screen also requires minimum scores for profitability, financial health, and growth. This combination is meant to identify stocks that are undervalued for cyclical or sentiment reasons rather than because the underlying fundamentals have permanently deteriorated. For value investors, that distinction is crucial; it is the difference between a genuine bargain and a value trap.
Valuation: relative value within a pricey industry
Globus Medical's valuation score of 7 out of 10 reflects a stock that is not in deep-value territory, but is clearly cheaper than most of its peers. The trailing P/E ratio stands at 17.41, and the forward P/E is 16.32. Both figures are well below the average for its industry group, where the trailing P/E is around 55.89, and also below the S&P 500's current average of roughly 26.06. The valuation case becomes even more interesting on a cash-flow basis: GMED is cheaper than 93.58% of its industry peers on price-to-free-cash-flow and cheaper than 90.37% on enterprise value to EBITDA.
The PEG ratio also points in the right direction. Because earnings are expected to grow around 13.19% per year, the current multiple looks more reasonable when adjusted for growth. That combination of below-market valuation and continued earnings growth is exactly what a value screen wants to capture. The full fundamental breakdown, including the scoring behind this valuation view, is available in the fundamental analysis report.
Profitability: margins and returns well above industry norms
The cheap valuation is supported by strong underlying profitability. Globus Medical earns a profitability rating of 8 out of 10, with several metrics ranking near the top of the Health Care Equipment & Supplies industry.
- Return on invested capital is 11.72%, outperforming 92.51% of industry peers.
- Return on equity is 11.23%, above 84.49% of the industry.
- Return on assets is 9.76%, above 89.30% of the industry.
- Operating margin is 21.42%, better than 94.65% of peers.
- Gross margin is 68.55%, better than 74.33% of peers.
- Profit margin is 17.03%, better than 91.98% of peers.
These are the kind of numbers that give a value investor confidence that the low multiple is not a reflection of weak pricing power or poor capital allocation. The company has also improved its operating margin over recent years, which suggests the profitability is not just a one-off result.
Financial health: a low-risk balance sheet
Another important safeguard is balance-sheet strength. Globus Medical carries essentially no debt, with a debt-to-equity ratio of 0.00 and a debt-to-free-cash-flow ratio of 0.00. Its Altman-Z score of 11.44 indicates a very low bankruptcy risk and ranks among the best in the industry. The current ratio of 4.62 and quick ratio of 2.93 also signal plenty of short-term liquidity.
A strong balance sheet matters for this strategy because it reduces the chance that an undervalued company becomes distressed before the market recognizes its true worth. It also gives management room to invest in growth or make acquisitions without taking on excessive leverage.
Growth: still expanding at a healthy pace
The final piece of the Decent Value screen is growth. Globus Medical has delivered impressive results in the past, and analysts still expect forward progress.
- EPS grew 53.27% last year and has grown at an average annual rate of 22.84% over the past years.
- Revenue grew 19.74% last year and has grown 30.08% per year on average over the past years.
- Future EPS growth is expected to average 13.72% per year.
- Future revenue growth is expected to average 8.25% per year.
The expected deceleration in growth is worth noting, but the projected figures are still solid for a company trading at a reasonable valuation. For value investors, the more important point is that the business is not stagnant. A low multiple combined with ongoing growth is a much more compelling proposition than a low multiple attached to a shrinking company.
Risks and limitations
No value screen can eliminate uncertainty. The expected slowdown in revenue and EPS growth could become more pronounced if competitive pressure in the musculoskeletal device market intensifies. The stock does not pay a dividend, which may make it less appealing to income-oriented value investors. And while the valuation is attractive relative to the industry, the absolute P/E is not extremely low, leaving less room for error if growth disappoints.
Other screens reinforce the same value-plus-quality story
GMED’s appearance in other Chartmill screens points the same way as the main value thesis.
- The High Free Cash Flow Stocks screen flags GMED’s strong free cash flow relative to its market price, adding a cash-flow check to the low-multiple argument.
- The High EPS Growth Stocks screen confirms that recent earnings growth is strong enough to stand on its own, supporting the growth side of the Decent Value case.
Taken together, these screens back the core conclusion: GMED is not merely cheap, but also financially sound and still growing.
Bottom line
Globus Medical fits the Decent Value model because it combines a relatively attractive valuation with above-average profitability, a very healthy balance sheet, and still-solid growth prospects. That combination addresses the biggest weakness of pure value strategies: buying a stock that looks cheap but stays cheap because the business is deteriorating. By requiring quality and growth alongside valuation, this screen narrows the field to companies that more closely resemble genuine bargains. Investors who want to scan for similar opportunities using the same methodology can find them through the Decent Value screen.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Globus Medical (NYSE:GMED): A Decent Value Stock With Solid Fundamentals
Value investors often look for stocks that are not just statistically cheap, but also financially sound enough to avoid the classic value trap. A practical way to combine those goals is to run a Decent Value screen, a methodology that requires a strong valuation score while still leaving room for decent profitability, health, and growth. GLOBUS MEDICAL INC - A (NYSE:GMED) is one company that currently passes that test, with a fundamental rating of 7 out of 10 and a balanced profile across the metrics that matter most for this strategy.
A screen designed to avoid value traps
The Decent Value screen starts with valuation, but it does not stop there. A low price-to-earnings ratio can sometimes point to a business in decline, so the screen also requires minimum scores for profitability, financial health, and growth. This combination is meant to identify stocks that are undervalued for cyclical or sentiment reasons rather than because the underlying fundamentals have permanently deteriorated. For value investors, that distinction is crucial; it is the difference between a genuine bargain and a value trap.
Valuation: relative value within a pricey industry
Globus Medical's valuation score of 7 out of 10 reflects a stock that is not in deep-value territory, but is clearly cheaper than most of its peers. The trailing P/E ratio stands at 17.41, and the forward P/E is 16.32. Both figures are well below the average for its industry group, where the trailing P/E is around 55.89, and also below the S&P 500's current average of roughly 26.06. The valuation case becomes even more interesting on a cash-flow basis: GMED is cheaper than 93.58% of its industry peers on price-to-free-cash-flow and cheaper than 90.37% on enterprise value to EBITDA.
The PEG ratio also points in the right direction. Because earnings are expected to grow around 13.19% per year, the current multiple looks more reasonable when adjusted for growth. That combination of below-market valuation and continued earnings growth is exactly what a value screen wants to capture. The full fundamental breakdown, including the scoring behind this valuation view, is available in the fundamental analysis report.
Profitability: margins and returns well above industry norms
The cheap valuation is supported by strong underlying profitability. Globus Medical earns a profitability rating of 8 out of 10, with several metrics ranking near the top of the Health Care Equipment & Supplies industry.
These are the kind of numbers that give a value investor confidence that the low multiple is not a reflection of weak pricing power or poor capital allocation. The company has also improved its operating margin over recent years, which suggests the profitability is not just a one-off result.
Financial health: a low-risk balance sheet
Another important safeguard is balance-sheet strength. Globus Medical carries essentially no debt, with a debt-to-equity ratio of 0.00 and a debt-to-free-cash-flow ratio of 0.00. Its Altman-Z score of 11.44 indicates a very low bankruptcy risk and ranks among the best in the industry. The current ratio of 4.62 and quick ratio of 2.93 also signal plenty of short-term liquidity.
A strong balance sheet matters for this strategy because it reduces the chance that an undervalued company becomes distressed before the market recognizes its true worth. It also gives management room to invest in growth or make acquisitions without taking on excessive leverage.
Growth: still expanding at a healthy pace
The final piece of the Decent Value screen is growth. Globus Medical has delivered impressive results in the past, and analysts still expect forward progress.
The expected deceleration in growth is worth noting, but the projected figures are still solid for a company trading at a reasonable valuation. For value investors, the more important point is that the business is not stagnant. A low multiple combined with ongoing growth is a much more compelling proposition than a low multiple attached to a shrinking company.
Risks and limitations
No value screen can eliminate uncertainty. The expected slowdown in revenue and EPS growth could become more pronounced if competitive pressure in the musculoskeletal device market intensifies. The stock does not pay a dividend, which may make it less appealing to income-oriented value investors. And while the valuation is attractive relative to the industry, the absolute P/E is not extremely low, leaving less room for error if growth disappoints.
Other screens reinforce the same value-plus-quality story
GMED’s appearance in other Chartmill screens points the same way as the main value thesis.
Taken together, these screens back the core conclusion: GMED is not merely cheap, but also financially sound and still growing.
Bottom line
Globus Medical fits the Decent Value model because it combines a relatively attractive valuation with above-average profitability, a very healthy balance sheet, and still-solid growth prospects. That combination addresses the biggest weakness of pure value strategies: buying a stock that looks cheap but stays cheap because the business is deteriorating. By requiring quality and growth alongside valuation, this screen narrows the field to companies that more closely resemble genuine bargains. Investors who want to scan for similar opportunities using the same methodology can find them through the Decent Value screen.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »